Successful testing of skin cancer vaccine

According to a recent announcement published in the journal Nature, American scientists have successfully tested a vaccine to prevent skin cancer.

The skin cancer vaccine, called NeoVax, contains up to 20 cancer antigens. Unlike traditional vaccines that prevent disease, NeoVax is designed to prevent malignant skin cancer cells from returning after melanoma has been surgically removed.

NeoVax was given to a group of six patients with skin cancer who had undergone surgery to remove melanoma. Patrick Ott, co-author of the skin cancer vaccine study at the Dana-Farber Cancer Institute in Boston, said NeoVax was active, safe and produced an immune response in all patients who received the vaccine. Typically, about half of cancer patients will relapse within two years of treatment. However, after 25 months, four patients in the trial group had no recurrence of melanoma.

This is a positive result but it is not comprehensive, the number of patients treated is quite low so there is still a possibility that patients who do not use the vaccine may not have had cancer recurrence.

There is a vaccine for prostate cancer, but it is not widely used. Other vaccines for the lung, bladder, and skin are in phase 2 trials in combination with another drug.

The initial success of NeoVax has confirmed the potential of cancer treatment with vaccines. Researchers will continue to test in the next phase on larger groups of participants to confirm the effectiveness of these vaccines./.

According to VOV